MedPath

Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Phase 3
Completed
Conditions
Insomnia Disorder
Interventions
Other: Placebo
Registration Number
NCT03575104
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Brief Summary

The main purpose of this study is to assess efficacy and safety of ACT-541468 (daridorexant) in adult and elderly subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
924
Inclusion Criteria
  • Signed informed consent prior to any study-mandated procedure;
  • Male or female aged ≥ 18 years;
  • Insomnia disorder according to DSM-5 criteria;
  • Insomnia Severity Index score ≥ 15;
  • Insufficient sleep quantity as collected subjectively in the sleep diary and validated objectively by polysomnography;
  • Women of childbearing potential must have a negative and urine pregnancy test and use the contraception scheme up to at least 30 days after last study treatment intake.
Exclusion Criteria
  • Body mass index below 18.5 or above 40.0 kg/m2;
  • Any lifetime history of of related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm disorder, rapid eye movement (REM) behavior disorder, narcolepsy, or apnea/hypopnea;
  • Cognitive behavioral therapy (CBT) only allowed if, the treatment started at least 1 month prior to Visit 3 and the subject agrees to continue this CBT throughout the study;
  • Self-reported usual daytime napping ≥ 1 hour per day and ≥ 3 days per week;
  • Acute or unstable psychiatric conditions diagnosed by the Mini International Neuropsychiatric Interview;
  • Mini Mental State Examination (MMSE) score < 25 in subjects ≥ 50 years;
  • For female subjects: pregnant, lactating or planning to become pregnant during projected duration of the study;
  • History or clinical evidence of any disease or medical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the study assessments.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo-
Daridorexant 25 mgDaridorexant-
Daridorexant 10 mgDaridorexant-
Primary Outcome Measures
NameTimeMethod
Change From Baseline to Month 1 in Latency to Persistent Sleep (LPS) (Sleep Onset)From baseline to Month 1 (i.e. for up to 1 month)

"Latency to Persistent Sleep" is the time from start of recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-awake, i.e., epochs scored as either sleep stage 1 (S1), sleep stage 2 (S2), sleep stage 3 (slow wave sleep) or REM, as determined by polysomnography.

Change From Baseline to Month 1 in Wake After Sleep Onset (WASO) (Sleep Maintenance)From baseline to Month 1 (i.e. for up to 1 month)

"Wake After Sleep Onset" is the time spent awake after onset of persistent sleep until lights on, as determined by polysomnography.

Change From Baseline to Month 3 in Latency to Persistent Sleep (LPS)From baseline to Month 3 (i.e. for up to 3 months)

"Latency to Persistent Sleep" is the time from start of recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-awake, i.e., epochs scored as either sleep stage 1 (S1), sleep stage 2 (S2), sleep stage 3 (slow wave sleep) or REM, as determined by polysomnography.

Change From Baseline to Month 3 in Wake After Sleep Onset (WASO)From baseline to Month 3 (i.e. for up to 3 months)

"Wake After Sleep Onset" is the time spent awake after onset of persistent sleep until lights on, as determined by polysomnography.

Secondary Outcome Measures
NameTimeMethod
Change From Baseline to Month 1 in the Subjective Total Sleep Time (sTST)From baseline to Month 1 (i.e. for up to 1 month)

"Subjective Total Sleep Time" is the total sleep time reported by the participant in the sleep diary questionnaire. A positive change from baseline indicates an increase in the subjective Total Sleep Time. A negative change from baseline indicates a decrease in subjective Total Sleep Time.

Change From Baseline to Month 3 in IDSIQ Sleepiness Domain ScoreFrom baseline to Month 3 (i.e. for up to 3 months)

The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) is a validated patient reported outcome instrument comprising 14 items (each using a numeric rating scale from 0 to 10) grouped into three domains (i.e., sleepiness, mood, and alert/cognition) reflecting daytime impairment of insomnia. The IDSIQ sleepiness domain has 4 items, and the domain score ranges from 0 to a maximum of 40, where a higher score indicates a greater burden. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

Change From Baseline to Month 3 in the Subjective Total Sleep Time (sTST)From baseline to Month 3 (i.e. for up to 3 months)

Subjective Total Sleep Time is the total sleep time reported by the participant in the sleep diary questionnaire. A positive change from baseline indicates an increase in the subjective Total Sleep Time. A negative change from baseline indicates a decrease in subjective Total Sleep Time.

Change From Baseline to Month 1 in Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) Sleepiness Domain ScoreFrom baseline to Month 1 (i.e. for up to 1 month)

The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) is a validated patient reported outcome instrument comprising 14 items (each using a numeric rating scale from 0 to 10) grouped into three domains (i.e., sleepiness, mood, and alert/cognition) reflecting daytime impairment of insomnia. The IDSIQ sleepiness domain has 4 items, and the domain score ranges from 0 to a maximum of 40, where a higher score indicates a greater burden. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

Trial Locations

Locations (85)

Canadian Phase Onward Inc.

🇨🇦

Toronto, Ontario, Canada

FutureSearch Trials of Neurology, LP

🇺🇸

Austin, Texas, United States

Neurotrials Research Incorporated

🇺🇸

Atlanta, Georgia, United States

Baptist Health Center for Clinical Research

🇺🇸

Little Rock, Arkansas, United States

Precise Research Centers

🇺🇸

Flowood, Mississippi, United States

Pacific Research Network

🇺🇸

San Diego, California, United States

CTI Clinical Research II

🇺🇸

Cincinnati, Ohio, United States

Hospital Universitair Zieknhuis Brussel, Pneumology and Sleep Laboratory

🇧🇪

Brussels, Belgium

University Hospital Gent, Department of General Internal Medicine and Center of neurophysiological Monitoring

🇧🇪

Gent, Belgium

Unitutkimusyksikkö, Turun Yliopisto

🇫🇮

Turku, Finland

CHRU De Lille - Hospital Salengro - Neurophysiologie Clinique

🇫🇷

Lille, France

Advanced Sleep Research GmbH

🇩🇪

Berlin, Germany

Klinische Forschung Berlin-Mitte GmbH

🇩🇪

Berlin, Germany

Synexus Clinical Research GmbH

🇩🇪

Frankfurt, Germany

Santa Monica Clinical Trials

🇺🇸

Santa Monica, California, United States

Rowe Neurology Institute

🇺🇸

Lenexa, Kansas, United States

Innovative Clinical Research

🇺🇸

Lafayette, Colorado, United States

Clinical Trials of America - NC, LLC

🇺🇸

Winston-Salem, North Carolina, United States

Core Healthcare Group

🇺🇸

Cerritos, California, United States

Pulmonary Associates, Pa

🇺🇸

Glendale, Arizona, United States

Noble Clinical Research

🇺🇸

Tucson, Arizona, United States

Woodland International Research Group

🇺🇸

Little Rock, Arkansas, United States

Artemis Institute for Clinical Research

🇺🇸

San Marcos, California, United States

Artemis Institute For Clinical Research - Riverside

🇺🇸

Riverside, California, United States

Empire Clinical Research

🇺🇸

Upland, California, United States

Clinical Research of South Florida

🇺🇸

Coral Gables, Florida, United States

Clinical Trials Research

🇺🇸

Lincoln, Florida, United States

Fleming Island Center for Clinical Research

🇺🇸

Fleming Island, Florida, United States

Clinical Research Group of St. Petersburgh

🇺🇸

Saint Petersburg, Florida, United States

Sleep Practitioners, LLC

🇺🇸

Macon, Georgia, United States

Saltzer Clinical Research

🇺🇸

Nampa, Idaho, United States

Sleep Disorders Center of the Mid-Atlantic

🇺🇸

Glen Burnie, Maryland, United States

Neurocare Inc.

🇺🇸

Newton, Massachusetts, United States

Research Carolina of Hickory

🇺🇸

Hickory, North Carolina, United States

Wake Research Associates

🇺🇸

Raleigh, North Carolina, United States

Ohio Sleep Medicine Institue

🇺🇸

Dublin, Ohio, United States

Cleveland Sleep Research Center

🇺🇸

Middleburg Heights, Ohio, United States

Robert V. Sibilia, MD, Inc.

🇺🇸

Wooster, Ohio, United States

Brian Abaluck LLC

🇺🇸

Paoli, Pennsylvania, United States

Wesley Neurology Clinic Pc (Multiple Sclerosis)

🇺🇸

Cordova, Tennessee, United States

InSite Clinical Research

🇺🇸

DeSoto, Texas, United States

Jacksonville Center for Clinical Research

🇺🇸

Jacksonville, Texas, United States

Dm Clinical Research / Martin Diagnostic Clinic

🇺🇸

Tomball, Texas, United States

HOSPITAL AZ SINT-JAN_Neurology department

🇧🇪

Brugge, Belgium

Hospital UZ Leuven_ Pneumology Department

🇧🇪

Leuven, Belgium

Narodni Ustav Dusevniho Zdravi (National Institute of Mental Health)

🇨🇿

Klecany, Czechia

Acibadem City Clinic Tokuda Hospital EAD

🇧🇬

Sofia, Bulgaria

The Medical Arts Health Research Group

🇨🇦

Kelowna, Canada

Somni Research Inc.

🇨🇦

Markham, Canada

Queensway Sleep Lab Sleep Clinic (MedSleep)- 5359 Dundas Street West, Suite 202, Etobicoke, ON M9B 1B1

🇨🇦

Etobicoke, Canada

Somni Research, Calgary

🇨🇦

Toronto, Canada

CANADIAN PHASE ONWARD INC. (Toronto)

🇨🇦

Toronto, Canada

Nemocnice České Budějovice, Centrum pro poruchy spánku a spánkovou medicínu

🇨🇿

České Budějovice, Czechia

Fakultní nemocnice Ostrava, Spánková laboratoř

🇨🇿

Ostrava-Poruba, Czechia

Vitalmed Uniklinikka

🇫🇮

Helsinki, Finland

Oivauni Oy - Kuopio

🇫🇮

Kuopio, Finland

Oivauni Oy - Tampere

🇫🇮

Tampere, Finland

Clinique beau soleil - Department Sleep and Neurology

🇫🇷

Montpellier, France

CHU NIMES - Unité de Sommeil

🇫🇷

Nîmes, France

Klinische Forschung Dresden GmbH

🇩🇪

Dresden, Germany

Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin Kompetenzzentrum Schlafmedizin

🇩🇪

Berlin, Germany

Interdisziplinäre Schlafmedizin, Pfalzklinikum

🇩🇪

Klingenmünster, Germany

Klinische Forschung Hannover Mitte GmbH

🇩🇪

Hannover, Germany

Zentrum für Integrative Psychiatrie (ZiP) Universität zu Lübeck

🇩🇪

Lübeck, Germany

Central Insitute of Mental Health Sleep laboratory Medical Faculty Mannheim/Heidelberg University

🇩🇪

Mannheim, Germany

Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie der Universität am Bezirksklinikum Regensburg

🇩🇪

Regensburg, Germany

4F Neuroimaging analysis laboratory, 56 Dalseong-ro, Jung-gu

🇰🇷

Daegu, Korea, Republic of

Magyar Honvédség Egészségügyi Központ, Neurológiai Osztály

🇭🇺

Budapest, Hungary

SOMNIBENE Institut für Medizinische Forschung und Schlafmedizin Schwerin GmbH

🇩🇪

Schwerin, Germany

Dong-A University Hospital

🇰🇷

Busan, Korea, Republic of

Chungnam National University Hospital

🇰🇷

Daejeon, Korea, Republic of

Somnius Kft. SomnoCenter Szeged

🇭🇺

Szeged, Hungary

3F, 2nd Building, Psychiatry Outpatient, Family Counseling Room, 42 Jebong-ro, Donggu

🇰🇷

Gwangju, Korea, Republic of

8F Sleep Lab, 1st Building,82, Gumi-ro 173 Beon-gil, Bundang-gu

🇰🇷

Seongnam, Korea, Republic of

B1F Neurological examination room, 892 Dongnam-ro, Gangdong-gu

🇰🇷

Seoul, Korea, Republic of

B2F, Clinical Trial Center, Konkuk University Medical Center 120-1, Neungdong-ro, Gwangjin-gu

🇰🇷

Seoul, Korea, Republic of

SOPHIAHEMMET (Stockholm)

🇸🇪

Stockholm, Sweden

2F Psychiatry Outpatient, 93, Jungbu-daero, Paldal-gu

🇰🇷

Suwon, Korea, Republic of

Göteborgs Universitet, Centrum för sömn och vakenhetsstörningar

🇸🇪

Göteborg, Sweden

Sömnutredningsmottagningen, smärtcentrum Akademiska sjukhuset

🇸🇪

Uppsala, Sweden

Universitetssjukhuset Örebro Neurokliniken, Sömnenheten

🇸🇪

Örebro, Sweden

3F Sleep Medicine Center, 101 Daehak-Ro Jongno-Gu

🇰🇷

Seoul, Korea, Republic of

1st CRC room, 2F, Jejoong building, 50-1 Yonsei-ro,, Seodaemun-gu

🇰🇷

Seoul, Korea, Republic of

Hawaii Pacific Neurosciences

🇺🇸

Honolulu, Hawaii, United States

Garden City Asthma and Sleep Center

🇺🇸

Garden City, New York, United States

© Copyright 2025. All Rights Reserved by MedPath